CG Oncology, Inc. (CGON) Price & Analysis

Compare

173 Followers

CGON Stock Chart & Stats

Day’s Range― - ―

52-Week Range$14.80 - $40.47

Previous Close$30.46

Volume740.02K

Average Volume (3M)819.68K

Market Cap

$2.06B

Enterprise Value$1.32B

Total Cash (Recent Filing)$661.05M

Total Debt (Recent Filing)$994.00K

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Nov 18, 2025

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding76,247,580

10 Day Avg. Volume530,835

30 Day Avg. Volume819,676

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.64

Enterprise Value/Revenue2.40K

Enterprise Value/Gross Profit3.35K

Enterprise Value/Ebitda-8.41

Forecast

1Y Price Target

$56.50

Price Target Upside113.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Legal VictoryCG Oncology wins lawsuit against ANI Pharmaceuticals, resulting in no royalty payments owed for cretostimogene.

Operational ImprovementsOperational improvements reduce procedure complexity and enhance viral potency retention, improving commercial readiness.

Regulatory ProgressCG Oncology's BLA submission for cretostimogene in BCG-unresponsive HR-NMIBC remains on track, with significant data expected soon.

Bears Say

Investor SentimentThe short interest in CG Oncology is 24%, indicating some skepticism among investors.

Trial RequirementsDespite positive topline data from phase 2 CORE-008 cohort A, the results are not sufficient for registration, requiring a much larger trial.

CG Oncology, Inc. News

CG Oncology initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of CG Oncology (CGON) with an Overweight rating and $55 price...

10d ago

CGON

CG Oncology initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of CG Oncology (CGON) with an Overweight rating and $55 price...

10d ago

CGON

CG Oncology price target lowered to $62 from $63 at BofA

BofA lowered the firm’s price target on CG Oncology (CGON) to $62 from $63 and keeps a Buy...

19d ago

CGON

CG Oncology reports Q2 EPS (54c), consensus (44c)

“In the second quarter, we announced best-in-disease durability and tolerability from the Phase 3 BOND-003 Cohort C registrational...

21d ago

CGON

CG Oncology’s Strategic Advancements and Promising Data Reinforce Buy Rating

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on CG Oncology, Inc. and keeping the...

18d ago

CGON

CG Oncology’s Q2 2025: Clinical Advances and Legal Wins

CG Oncology, Inc. ( ($CGON) ) has released its Q2 earnings. Here is a breakdown of the information...

20d ago

CGON

Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. and keeping the price...

21d ago

CGON

Positive Outlook for CG Oncology: Legal Victory and Promising Milestones Drive Buy Rating

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc.. The associated price...

1M ago

CGON

CG Oncology announces Delaware Superior Court ruling in its favor

CG Oncology (CGON) (CG) announced that a jury in the Superior Court of the State of Delaware unanimously...

1M ago

ANIP

CGON

CG Oncology price target lowered to $53 from $68 at RBC Capital

RBC Capital lowered the firm’s price target on CG Oncology (CGON) to $53 from $68 and keeps an...

1M ago

CGON

CG Oncology Appoints Interim CFO After Resignation

CG Oncology, Inc. ( ($CGON) ) has issued an announcement. CG Oncology, Inc. announced that its Chief Financial...

2M ago

CGON

CG Oncology resumed with a Buy at Goldman Sachs

Goldman Sachs resumed coverage of CG Oncology (CGON) with a Buy rating and $40 price target The firm...

2M ago

CGON

CG Oncology price target raised to $56 from $52 at Morgan Stanley

Morgan Stanley raised the firm’s price target on CG Oncology (CGON) to $56 from $52 and keeps an...

2M ago

CGON

CG Oncology Holds 2025 Annual Stockholders Meeting

CG Oncology, Inc. ( ($CGON) ) just unveiled an update. On June 5, 2025, CG Oncology, Inc. held...

3M ago

CGON

CGON FAQ

What was CG Oncology, Inc.’s price range in the past 12 months?

CG Oncology, Inc. lowest stock price was $14.80 and its highest was $40.47 in the past 12 months.

What is CG Oncology, Inc.’s market cap?

CG Oncology, Inc.’s market cap is $2.06B.

When is CG Oncology, Inc.’s upcoming earnings report date?

CG Oncology, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 81 days.

How were CG Oncology, Inc.’s earnings last quarter?

CG Oncology, Inc. released its earnings results on Aug 08, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.466 by -$0.074.

Is CG Oncology, Inc. overvalued?

According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CG Oncology, Inc. pay dividends?

CG Oncology, Inc. does not currently pay dividends.

What is CG Oncology, Inc.’s EPS estimate?

CG Oncology, Inc.’s EPS estimate is -0.56.

How many shares outstanding does CG Oncology, Inc. have?

CG Oncology, Inc. has 76,247,580 shares outstanding.

What happened to CG Oncology, Inc.’s price movement after its last earnings report?

CG Oncology, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.466. Following the earnings report the stock price went up 2.053%.

Which hedge fund is a major shareholder of CG Oncology, Inc.?

Currently, no hedge funds are holding shares in CGON

CG Oncology, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-20.95%

Trailing 12-Months

Asset Growth

24.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CG Oncology, Inc.

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology, Inc. (CGON) Earnings & Revenues

Historic Earnings Reports

CGON Stock 12 Month Forecast

Average Price Target

$56.50

▲(113.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","52":"$52","83":"$83","36.5":"$36.5","67.5":"$67.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,36.5,52,67.5,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.31,30.59384615384615,34.87769230769231,39.16153846153846,43.44538461538461,47.72923076923077,52.01307692307692,56.29692307692308,60.580769230769235,64.86461538461539,69.14846153846155,73.43230769230769,77.71615384615384,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.31,28.63230769230769,30.954615384615384,33.276923076923076,35.59923076923077,37.92153846153846,40.24384615384615,42.566153846153846,44.88846153846154,47.21076923076923,49.53307692307692,51.855384615384615,54.17769230769231,{"y":56.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.31,26.439999999999998,26.57,26.7,26.83,26.96,27.09,27.22,27.349999999999998,27.48,27.61,27.74,27.87,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >